IL17A and psoriasis: Additional cytokine blocking agents targeting IL-6 (a factor during effector Th17 T-cell differentiation) or the IL-23/IL-17 axis have been considered for SAPHO because of clinical overlaps with psoriasis and spondylarthritis.23 24 54 Nine patients were treated across three studies from China, France and Australia.